paroxetine

Summary

Summary: A serotonin uptake inhibitor that is effective in the treatment of depression.

Top Publications

  1. ncbi Paroxetine for the prevention of depression induced by high-dose interferon alfa
    D L Musselman
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
    N Engl J Med 344:961-6. 2001
  2. ncbi Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions
    Lucile Capuron
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1639 Pierce Drive, Atlanta, GA 30322, USA
    Neuropsychopharmacology 26:643-52. 2002
  3. ncbi Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment
    Lucile Capuron
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Biol Psychiatry 54:906-14. 2003
  4. pmc Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels
    N P Tatonetti
    Biomedical Informatics Training Program, Stanford University, Stanford, California, USA
    Clin Pharmacol Ther 90:133-42. 2011
  5. ncbi Perinatal outcome following third trimester exposure to paroxetine
    Adriana Moldovan Costei
    The Motherisk Program, Division of Clinical Pharmacology Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada
    Arch Pediatr Adolesc Med 156:1129-32. 2002
  6. ncbi Inhibition of G protein-activated inwardly rectifying K+ channels by the antidepressant paroxetine
    Toru Kobayashi
    Department of Molecular Neuropathology, Brain Research Institute, Niigata University, Niigata, Japan
    J Pharmacol Sci 102:278-87. 2006
  7. doi A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)
    Susan L McElroy
    Lindner Center of HOPE Research Institute, Mason, OH 45040, USA
    J Clin Psychiatry 71:163-74. 2010
  8. ncbi Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression
    S H Kennedy
    Mood and Anxiety Disorders Program, Centre for Addiction and Mental Health, Clarke Site, 250 College St, Toronto, Ontario M5T 1R8, Canada
    Am J Psychiatry 158:899-905. 2001
  9. ncbi Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors
    Benjamin Bar-Oz
    Motherisk Program, The Hospital for Sick Children, Toronto, Ontario, Canada
    Clin Ther 29:918-26. 2007
  10. ncbi Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures
    Vikram K Yeragani
    Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan, USA
    Biol Psychiatry 52:418-29. 2002

Detail Information

Publications287 found, 100 shown here

  1. ncbi Paroxetine for the prevention of depression induced by high-dose interferon alfa
    D L Musselman
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
    N Engl J Med 344:961-6. 2001
    ..eligible for high-dose interferon alfa therapy, we randomly assigned 20 patients to receive the antidepressant paroxetine and 20 to receive placebo...
  2. ncbi Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions
    Lucile Capuron
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1639 Pierce Drive, Atlanta, GA 30322, USA
    Neuropsychopharmacology 26:643-52. 2002
    ..melanoma undergoing interferon-alpha (IFN-alpha) therapy can be reduced by pretreatment with the antidepressant, paroxetine. Using dimensional analyses, the present study assessed the expression and treatment responsiveness of specific ..
  3. ncbi Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment
    Lucile Capuron
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Biol Psychiatry 54:906-14. 2003
    ..Tryptophan (TRP) degradation into kynurenine (KYN) by the enzyme, indoleamine-2,3-dioxygenase, during immune activation may contribute to development of depressive symptoms during interferon (IFN)-alpha therapy...
  4. pmc Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels
    N P Tatonetti
    Biomedical Informatics Training Program, Stanford University, Stanford, California, USA
    Clin Pharmacol Ther 90:133-42. 2011
    The lipid-lowering agent pravastatin and the antidepressant paroxetine are among the most widely prescribed drugs in the world. Unexpected interactions between them could have important public health implications...
  5. ncbi Perinatal outcome following third trimester exposure to paroxetine
    Adriana Moldovan Costei
    The Motherisk Program, Division of Clinical Pharmacology Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada
    Arch Pediatr Adolesc Med 156:1129-32. 2002
    b>Paroxetine hydrochloride is commonly used for maternal depression, panic disorder, and obsessive-compulsive disorder. The drug readily crosses the human placenta...
  6. ncbi Inhibition of G protein-activated inwardly rectifying K+ channels by the antidepressant paroxetine
    Toru Kobayashi
    Department of Molecular Neuropathology, Brain Research Institute, Niigata University, Niigata, Japan
    J Pharmacol Sci 102:278-87. 2006
    b>Paroxetine is commonly used as a selective serotonin reuptake inhibitor for the treatment of depression and other psychiatric disorders. However, the molecular mechanisms of the paroxetine effects have not yet been sufficiently clarified...
  7. doi A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)
    Susan L McElroy
    Lindner Center of HOPE Research Institute, Mason, OH 45040, USA
    J Clin Psychiatry 71:163-74. 2010
    The aim of this study was to evaluate the efficacy and tolerability of quetiapine and paroxetine monotherapy for major depression in bipolar disorder.
  8. ncbi Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression
    S H Kennedy
    Mood and Anxiety Disorders Program, Centre for Addiction and Mental Health, Clarke Site, 250 College St, Toronto, Ontario M5T 1R8, Canada
    Am J Psychiatry 158:899-905. 2001
    ..The aim of the present study was to assess the effects of successful paroxetine treatment on regional glucose metabolism in patients with major depression.
  9. ncbi Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors
    Benjamin Bar-Oz
    Motherisk Program, The Hospital for Sick Children, Toronto, Ontario, Canada
    Clin Ther 29:918-26. 2007
    Antidepressants have been commonly used by women of childbearing age. Recent studies suggest that paroxetine, a selective serotonin reuptake inhibitor (SSRI), might specifically increase teratogenic risk.
  10. ncbi Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures
    Vikram K Yeragani
    Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan, USA
    Biol Psychiatry 52:418-29. 2002
    ..Recent studies have shown decreased vagal function in cardiac patients with depression and depressed patients without cardiac illness...
  11. doi A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome
    Prakash S Masand
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, 1001 Winstead Dr, Suite 200, Cary, NC 27513, USA
    Psychosomatics 50:78-86. 2009
    ..Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disease that causes significant impairment in quality of life and accounts for $8 billion per year to the healthcare system and loss of productivity in the workplace...
  12. doi First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies
    Keele E Wurst
    Worldwide Epidemiology, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    Birth Defects Res A Clin Mol Teratol 88:159-70. 2010
    Several studies have evaluated maternal first trimester paroxetine use and the prevalence of congenital defects, particularly cardiac defects. To synthesize current epidemiologic information, a meta-analysis was conducted.
  13. doi Changes in brain protein expression are linked to magnesium restriction-induced depression-like behavior
    Nigel Whittle
    Department of Pharmacology and Toxicology and Center for Molecular Biosciences, University of Innsbruck, Innsbruck, Austria
    Amino Acids 40:1231-48. 2011
    ..Aberrant expressions of DDAH1, MnSOD and GDH1 were normalized by chronic paroxetine treatment which also normalized the enhanced depression-like behavior, strengthening the link between the ..
  14. ncbi Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment
    M Fava
    Massachusetts General Hospital, Boston 02114, USA
    J Clin Psychiatry 61:863-7. 2000
    ..Also unknown is whether different agents have differential effects. To examine these questions, we assessed weight changes in patients randomly assigned to long-term treatment with fluoxetine, sertraline, or paroxetine.
  15. ncbi A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling
    Suck Won Kim
    Department of Psychiatry, University of Minnesota, Minneapolis, USA
    J Clin Psychiatry 63:501-7. 2002
    This randomized, double-blind, placebo-controlled study investigated the efficacy and tolerability of paroxetine in the treatment of pathological gambling.
  16. ncbi Effect of paroxetine on enhanced contextual fear induced by single prolonged stress in rats
    Terumichi Takahashi
    Department of Psychiatry and Neurosciences, Division of Frontier Medical Science, Hiroshima University, Minami Ku, Hiroshima, 734 8551, Japan
    Psychopharmacology (Berl) 189:165-73. 2006
    ..Single prolonged stress (SPS) is an animal model of posttraumatic stress disorder (PTSD) that can reproduce enhanced hypothalamo-pituitary-adrenal negative feedback...
  17. pmc A controlled trial of antidepressants in patients with Parkinson disease and depression
    M Menza
    Department of Psychiatry, Robert Wood Johnson Medical School, UMDNJ University Behavioral Health Care, Piscataway, NJ 08854, USA
    Neurology 72:886-92. 2009
    ..Depression affects up to 50% of these patients and is associated with a variety of poor outcomes for patients and their families. Despite this, there are few evidence-based data to guide clinical care...
  18. ncbi Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics
    Magi Farre
    Pharmacology Research Unit, Institut Municipal d Investigació Mèdica Hospital del Mar, Doctor Aiguader 88, E 08003 Barcelona, Spain
    J Pharmacol Exp Ther 323:954-62. 2007
    ..A clinical trial was designed where subjects pretreated with paroxetine, one of the most potent inhibitors of both 5-hydroxytryptamine reuptake and CYP2D6 activity, were challenged ..
  19. doi Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine
    Inge Sillaber
    Max Planck Institute of Psychiatry, 80804 Munich, Germany
    Psychopharmacology (Berl) 200:557-72. 2008
    ..Monoamine-based antidepressants inhibit neurotransmitter reuptake within short time. However, it commonly takes several weeks until clinical symptoms start to resolve--indicating the involvement of effects distant from reuptake inhibition...
  20. ncbi Paroxetine in the first trimester and the prevalence of congenital malformations
    J Alexander Cole
    i3 Drug Safety, Auburndale, MA, USA
    Pharmacoepidemiol Drug Saf 16:1075-85. 2007
    To refine a preliminary analysis identifying a possibly increased prevalence of malformations among infants born to women exposed to paroxetine in the first trimester.
  21. ncbi Persistent neuroendocrine and behavioral effects of a novel, etiologically relevant mouse paradigm for chronic social stress during adolescence
    M V Schmidt
    Max Planck Institute of Psychiatry, RG Molecular Stress Physiology, Kraepelinstr 2 10, 80804 Munich, Germany
    Psychoneuroendocrinology 32:417-29. 2007
    ..In addition, pharmacological treatments with the antidepressant paroxetine (SSRI) or with the corticotropin-releasing hormone receptor 1 antagonist DMP696 were able to prevent aversive ..
  22. ncbi Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings
    A L Brody
    Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, CA, USA
    Arch Gen Psychiatry 58:631-40. 2001
    ..We also performed a preliminary comparison of regional changes with 2 distinct forms of treatment (paroxetine and interpersonal psychotherapy).
  23. doi Block of persistent late Na+ currents by antidepressant sertraline and paroxetine
    Ging Kuo Wang
    Department of Anesthesia, Harvard Medical School and Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Membr Biol 222:79-90. 2008
    ..In this report, we examined the effects of contemporary antidepressants sertraline and paroxetine on (1) neuronal Na+ channels expressed in GH3 cells and (2) muscle rNav1...
  24. ncbi Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine
    Jun Fujishiro
    Pharmaceutical Research Center, Meiji Seika Kaisha Ltd, 760 Morooka cho, Kohoku, Yokohama 222 8567, Japan
    Eur J Pharmacol 454:183-8. 2002
    b>Paroxetine, a selective serotonin reuptake inhibitor, shows relatively high affinity for muscarinic acetylcholine receptors compared to other selective serotonin reuptake inhibitors...
  25. doi Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis
    Dawn M Ehde
    Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA
    Gen Hosp Psychiatry 30:40-8. 2008
    The objective of this study was to evaluate the efficacy of paroxetine in treating major depressive disorder (MDD) in persons with multiple sclerosis (MS).
  26. doi A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder
    Dirk Wedekind
    Department of Psychiatry and Psychotherapy, University of Goettingen, Goettingen, Germany
    World J Biol Psychiatry 11:904-13. 2010
    ..Regular aerobic exercise (running) has been shown to be superior to a pill placebo in the treatment of panic disorder. Combined drug and exercise treatment has not been investigated in randomized controlled studies to date...
  27. ncbi Paroxetine-induced modulation of cortical activity supporting language representations of action
    Patrice Peran
    INSERM U825, CHU Purpan, Toulouse 31059, France
    Psychopharmacology (Berl) 195:487-96. 2008
    Previous studies have shown that paroxetine, a selective serotonin reuptake inhibitor, affects brain motor pathway activity in healthy subjects using simple motor tasks...
  28. ncbi Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline
    G Pezzella
    Azienda Ospedaliera Santissinia Annunziata, Unita Operativa di Oncologia Medica, Taranto, Italy
    Breast Cancer Res Treat 70:1-10. 2001
    ..parallel-group study in which 179 women with breast cancer were randomized to treatment with either the SSRI paroxetine (20-40 mg/day), or the TCA, amitriptyline (75-150 mg/day)...
  29. ncbi A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression
    Dominique L Musselman
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Clin Psychiatry 67:288-96. 2006
    This study compared the efficacy and safety of paroxetine and desipramine with those of placebo in the treatment of depressive disorders in adult women with breast cancer, stages I-IV.
  30. doi Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy
    Adrienne Einarson
    Motherisk Program, Hospital for Sick Children, Division of Clinical Pharmacology, University of Toronto, 555 University Ave, Toronto, Ontario M5G 1X8, Canada
    Am J Psychiatry 165:749-52. 2008
    ..several studies noted an increased risk of cardiovascular birth defects associated with maternal use of paroxetine compared with other antidepressants in the same class...
  31. doi Effects of intrathecal administration of newer antidepressants on mechanical allodynia in rat models of neuropathic pain
    Tetsuya Ikeda
    Division of Neurobiology, Faculty of Medicine, University of Miyazaki, Kiyotake, Miyazaki 889 1692, Japan
    Neurosci Res 63:42-6. 2009
    ..more fully clarified were selected, milnacipran, a serotonin and noradrenaline reuptake inhibitor (SNRI) and paroxetine and fluvoxamine, which are selective serotonin reuptake inhibitors (SSRIs)...
  32. ncbi Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial
    M Langemark
    Department of Neurology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
    Headache 34:20-4. 1994
    ..A serotonin re-uptake inhibitor, paroxetine (20-30 mg daily), and a dopamine antagonist, sulpiride (200-400 mg daily) were compared in a randomized, double-..
  33. pmc Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion
    Birgit Abler
    Department of Psychiatry, University of Ulm, Ulm, Germany
    Neuropsychopharmacology 36:1837-47. 2011
    Sexual dysfunction is a common side effect of selective serotonin reuptake inhibitors (SSRIs) like paroxetine in the treatment of depression, imposing a considerable risk on medication adherence and hence therapeutic success...
  34. ncbi Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients
    A J Elliott
    Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98104, USA
    Am J Psychiatry 155:367-72. 1998
    This study examined whether a selective serotonin reuptake inhibitor (paroxetine) had comparable efficacy but greater tolerability than a tricyclic antidepressant (imipramine) in depressed patients with HIV infection.
  35. doi A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression
    Yiru Fang
    Division of Mood Disorders, Shanghai Mental Health Center, Department of Psychiatry, Shanghai Jiao Tong University School of Medicine, Shanghai, China
    J Clin Psychopharmacol 31:638-42. 2011
    To compare the efficacy and safety of augmenting paroxetine with risperidone, buspirone, valproate, trazodone, or thyroid hormone in patients with treatment-resistant depression (TRD), 225 patients with retrospectively and/or ..
  36. doi Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: a reanalysis of a randomized, double-blind study
    Maximilian Pilhatsch
    Dept of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universitat, Dresden, Germany
    J Affect Disord 126:453-7. 2010
    To compare the efficacy and safety of adjunctive treatment with paroxetine or amitriptyline in patients with bipolar disorder who relapsed into a depressive episode during lithium maintenance therapy.
  37. ncbi Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy
    Joseph A Roscoe
    University of Rochester Cancer Center, 601 Elmwood Avenue, Box 704, Rochester, New York 14642, USA
    Breast Cancer Res Treat 89:243-9. 2005
    ..It commonly co-exists with depression in patients undergoing chemotherapy, suggesting that administration of an antidepressant that alleviates symptoms of depression could also reduce fatigue...
  38. ncbi Controlled-release paroxetine in the treatment of patients with social anxiety disorder
    Ulla Lepola
    Department of Psychiatry, University of Helsinki, Helsinki, Finland
    J Clin Psychiatry 65:222-9. 2004
    This double-blind, placebo-controlled, flexible-dose study was conducted to investigate the efficacy and tolerability of the controlled-release (CR) formulation of paroxetine in adults with social anxiety disorder.
  39. pmc Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects
    Manon J van der Lee
    Department of Clinical Pharmacy, Radboud University Medical Centre Nijmegen, Geert Grooteplein 10, 6525 GA Nijmegen, The Netherlands
    Antimicrob Agents Chemother 51:4098-104. 2007
    ..Theoretically, ritonavir-boosted protease inhibitors may inhibit CYP2D6-mediated metabolism of paroxetine. We wanted to determine the effect of fosamprenavir-ritonavir on paroxetine pharmacokinetics and vice versa and ..
  40. pmc The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease
    Matthew Menza
    Department of Psychiatry, Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA
    Mov Disord 24:1325-32. 2009
    ..This was an NIH-funded, randomized, controlled trial of paroxetine, nortriptyline, and placebo. It included an 8 week acute phase and a 16 week blind extension phase...
  41. ncbi Modulation of the suppressive effect of corticosterone on adult rat hippocampal cell proliferation by paroxetine
    Guang Qiu
    Department of Anatomy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, HKSAR, China
    Neurosci Bull 23:131-6. 2007
    ..b>Paroxetine, a selective serotonin reuptake transporter, is a commonly used antidepressant for alleviation of signs and ..
  42. pmc A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease
    I H Richard
    University of Rochester, Rochester, NY, USA
    Neurology 78:1229-36. 2012
    ..To evaluate the efficacy and safety of a selective serotonin reuptake inhibitor (SSRI) and a serotonin and norepinephrine reuptake inhibitor (SNRI) in the treatment of depression in Parkinson disease (PD)...
  43. ncbi Adverse effect of paroxetine on sperm
    Cigdem Tanrikut
    James Buchanan Brady Foundation, Department of Urology, Cornell Reproductive Medicine Institute, Weill Medical College of Cornell University, New York, New York 10021, USA
    Fertil Steril 94:1021-6. 2010
    ..To assess the effects of a selective serotonin reuptake inhibitor on semen parameters...
  44. ncbi Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells
    Lynn W Maines
    Department of Pharmacology, The Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA
    Neuropharmacology 49:610-7. 2005
    ..In contrast, neither verapamil nor PGP-4008 affected the intracellular accumulation of [3H]paroxetine, [14C]phenytoin, [3H]clozapine or [14C]carbamazapine, indicating that these drugs are not substrates for Pgp...
  45. ncbi Paroxetine treatment improves motor symptoms in patients with multiple system atrophy
    Elisabeth Friess
    Max Planck Institute of Psychiatry, Kraepelinstr 10, 80804 Munich, Germany
    Parkinsonism Relat Disord 12:432-7. 2006
    ..of the putative role of serotonergic neurotransmission in basal ganglia circuitry we investigated the effects of paroxetine (PXT) as a selective serotonin reuptake inhibitor (SSRI) on the motor performance in n=19 patients clinically ..
  46. doi Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease
    Young C Chung
    Neuroscience Graduate Program, School of Medicine, Ajou University, Suwon, South Korea
    J Immunol 185:1230-7. 2010
    The present study examined whether the antidepressant paroxetine promotes the survival of nigrostriatal dopaminergic (DA) neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease...
  47. ncbi Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe
    Mireia Segura
    Pharmacology Research Unit, Barcelona, Spain
    Clin Pharmacokinet 44:649-60. 2005
    ..This study was aimed at assessing the contribution of CYP2D6 to MDMA disposition in vivo using paroxetine as a metabolic probe inhibitor...
  48. ncbi Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C
    C L Raison
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA
    Aliment Pharmacol Ther 25:1163-74. 2007
    ..Whether antidepressants prevent depression during interferon-alpha/ribavirin treatment for hepatitis C virus infection has yet to be established...
  49. ncbi Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram)
    Craig H Mallinckrodt
    Lilly Research Laboratories, Indianapolis, Ind 46285, USA
    Neuropsychobiology 56:73-85. 2007
    ....
  50. ncbi A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder
    Damiaan Denys
    Department of Psychiatry, University Medical Center B 01 206, PO Box 85500, 3508 GA Utrecht, The Netherlands
    J Clin Psychopharmacol 23:568-75. 2003
    ..The current study compares the efficacy and tolerability of venlafaxine with paroxetine. One hundred and fifty patients with primary OCD according to DSM-IV criteria were randomly assigned in a 12-..
  51. ncbi A randomized, placebo-controlled trial of paroxetine in nursing home residents with non-major depression
    Adam B Burrows
    Geriatrics Section, Boston University School of Medicine, 74 Fenwood Road, Boston, MA 02115, USA
    Depress Anxiety 15:102-10. 2002
    ..We conducted a randomized double-blind placebo-controlled 8-week trial comparing paroxetine and placebo in very old nursing home residents with non-major depression...
  52. ncbi Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial
    Jon E Grant
    Department of Psychiatry, University of Minnesota Medical School, Minneapolis, Minnesota 55454 1495, USA
    Int Clin Psychopharmacol 18:243-9. 2003
    ..The aim of the present study was to determine whether treatment with paroxetine in a large sample of subjects with pathological gambling would effectively diminish the severity of gambling ..
  53. ncbi Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study
    R D Marshall
    Anxiety Disorders Clinic, Unit 69, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Am J Psychiatry 158:1982-8. 2001
    This study evaluated the efficacy and safety of paroxetine for the treatment of patients with chronic posttraumatic stress disorder (PTSD).
  54. ncbi The use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial
    Shaila Misri
    Department of, Faculty of Medicine, University of British Columbia and Reproductive Mental Health Programs, St Paul s Hospital, Vancouver, British Columbia, Canada
    J Clin Psychiatry 65:1236-41. 2004
    ....
  55. doi Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale
    A L Montejo
    Servicio de Psiquiatria, Hospital Universitario de Salamanca, Salamanca, Spain
    J Psychopharmacol 24:111-20. 2010
    ..Sexual acceptability of agomelatine (a melatonergic agonist and 5HT(2C) antagonist) paroxetine and placebo by using the Psychotropic-Related Sexual Dysfunction Salamanca Sex Questionnaire (PRSEXDQ-SALSEX) ..
  56. ncbi Paroxetine-induced hyponatremia in older adults: a 12-week prospective study
    Tanya J Fabian
    Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Arch Intern Med 164:327-32. 2004
    ..are at high risk for development of hyponatremia after initiation of the selective serotonin reuptake inhibitor paroxetine, despite clinical monitoring and preventive management...
  57. ncbi Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption
    Manfred Uhr
    Max Planck Institute of Psychiatry, Kraepelinstrasse 10, D 80804 Munich, Germany
    Biol Psychiatry 54:840-6. 2003
    ..used to examine the effect of the absence of the drug-transporting P-glycoprotein (P-gp) at the blood-brain barrier on the uptake of the antidepressants venlafaxine, paroxetine, mirtazapine, and doxepin and its metabolites into the brain.
  58. ncbi RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine
    Stephanie Tucker
    Neurochemistry Laboratory, Division of Psychiatric Neurosciences and Genetics and Aging Research Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Curr Alzheimer Res 3:221-7. 2006
    Lead compounds directed to the 5' leader of the Amyloid Precursor Protein transcript (i.e., paroxetine (SSRI), N-acetyl cysteine (antioxidant), and erythromycin (macrolide antibiotic)) were employed in a pilot study to evaluate their anti-..
  59. doi Evaluation of Krebs cycle enzymes in the brain of rats after chronic administration of antidepressants
    Giselli Scaini
    Laboratório de Fisiopatologia Experimental, Programa de Pos Graduacao em Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, SC, Brazil
    Brain Res Bull 82:224-7. 2010
    ..citrate synthase and succinate dehydrogenase activities from rat brain after chronic administration of paroxetine, nortriptiline and venlafaxine...
  60. ncbi Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program
    Gary R Morrow
    James P Wilmot Cancer Center and Department of Biostatistics, University of Rochester Medical Center, NY 14642, USA
    J Clin Oncol 21:4635-41. 2003
    ..This randomized clinical trial tested whether paroxetine, a selective serotonin reuptake inhibitor antidepressant known to modulate brain serotonin, would reduce fatigue ..
  61. ncbi Prenatal maternal paroxetine treatment and neonatal mortality in the rat: a preliminary study
    Daniel L A van den Hove
    Department of Psychiatry and Neuropsychology, Research Institute Brain and Behavior, European Graduate School of Neuroscience, Maastricht University, Maastricht, The Netherlands
    Neonatology 93:52-5. 2008
    ..Our aim was to examine the efficacy of using the selective serotonin reuptake inhibitor, paroxetine, to alleviate the symptoms of prenatal maternal stress in Fisher 344 rats...
  62. ncbi Cognitive behavior therapy and paroxetine in the treatment of hypochondriasis: a randomized controlled trial
    Anja Greeven
    Department of Clinical and Health Psychology, Leiden University, The Netherlands
    Am J Psychiatry 164:91-9. 2007
    ..study, to the authors' knowledge, is the first randomized controlled trial comparing the efficacy of cognitive behavior therapy (CBT), paroxetine, and a placebo (administered in a double blind fashion) in the treatment of hypochondriasis.
  63. ncbi Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder
    Michael R Liebowitz
    New York State Psychiatric Institute, New York 10032, USA
    Arch Gen Psychiatry 62:190-8. 2005
    ..Evidence indicates that venlafaxine hydrochloride extended release (ER) effectively ameliorates anxiety symptoms...
  64. ncbi In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude
    Karthik Venkatakrishnan
    Department of Clinical Pharmacokinetics and Pharmacodynamics, Pfizer Global Research and Development, Groton, CT 06340, USA
    Drug Metab Dispos 33:845-52. 2005
    Attempts at predicting drug-drug interactions perpetrated by paroxetine from in vitro data have utilized reversible enzyme inhibition models and have been unsuccessful to date, grossly underpredicting interaction magnitude...
  65. pmc Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief
    Kenichiro Nagata
    Department of Molecular and System Pharmacology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan
    Mol Pain 5:20. 2009
    ..We investigated a possible role of antidepressants as inhibitors of P2X4 receptors and analysed their analgesic mechanism using an animal model of neuropathic pain...
  66. ncbi A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder
    David S Baldwin
    Clinical Neuroscience Division, University of Southampton, Royal South Hants Hospital, Southampton, UK
    Int Clin Psychopharmacol 21:159-69. 2006
    ..study evaluated the short- and long-term antidepressant tolerability and efficacy of escitalopram and paroxetine. Tolerability was assessed by monitoring adverse events throughout the study, and discontinuation events during ..
  67. ncbi Proteomic analysis of rat hippocampus exposed to the antidepressant paroxetine
    P C McHugh
    Department of Pathology, University of Otago, Christchurch, New Zealand
    J Psychopharmacol 24:1243-51. 2010
    ..Rats were administered either 5 mg/kg daily of the antidepressant paroxetine or vehicle for 12 days, then hippocampal protein was recovered and resolved by 2-D gel electrophoresis...
  68. ncbi Clinical and neurobiological effects of tianeptine and paroxetine in major depression
    Thomas Nickel
    Max Planck Institute of Psychiatry, Munich, Germany
    J Clin Psychopharmacol 23:155-68. 2003
    ..between these two opposite pharmacological modes of action, we compared the changes induced by tianeptine and paroxetine on psychopathology, the hypothalamic-pituitary-adrenocortical (HPA) system, and cognitive functions in a double-..
  69. doi The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets
    J Berwaerts
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ 08560, USA
    Pharmacopsychiatry 42:158-63. 2009
    ..As such, selecting antipsychotic medications with a low potential for drug-drug interactions (DDIs) is crucial, as many are extensively metabolized by hepatic cytochrome P450 (CYP) isozymes...
  70. ncbi The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study
    J H Meyer
    Clarke Division, Centre for Addictions and Mental Health, Department ofPsychiatry, University of Toronto, Ontario, Canada
    Am J Psychiatry 158:78-85. 2001
    ..The objective of this study was to evaluate the effect of 6 weeks of paroxetine treatment on 5-HT(2A) receptors in depressed patients.
  71. ncbi Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine
    Eric Hollander
    Department of Psychiatry, Box 1230, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029 6574, USA
    J Clin Psychiatry 64:1113-21. 2003
    ..This study evaluated the acute safety and efficacy and long-term efficacy, safety, and impact on relapse prevention of paroxetine in obsessive-compulsive disorder.
  72. ncbi A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C
    Benjamin J Morasco
    Behavioral Health and Clinical Neurosciences Division, Portland VA Medical Center, Oregon, United States
    J Affect Disord 103:83-90. 2007
    ..This study examined the efficacy of paroxetine in preventing the development of depression during antiviral therapy.
  73. ncbi Transient ischemic attack reported with paroxetine use
    Gail H Manos
    Department of Psychiatry, Naval Medical Center Portsmouth, Portsmouth, VA 23708 2197, USA
    Ann Pharmacother 38:617-20. 2004
    To report the occurrence of a transient ischemic attack (TIA) temporally related to the initiation of paroxetine.
  74. ncbi Paroxetine inhibits acute effects of 3,4-methylenedioxymethamphetamine on the immune system in humans
    Roberta Pacifici
    Istituto Superiore di Sanita, Rome, Italy
    J Pharmacol Exp Ther 309:285-92. 2004
    The effect of pretreatment with paroxetine on cell-mediated immune response and release of cytokines after the administration of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") was investigated in a double-blind, randomized, ..
  75. ncbi [Clinical observation on treatment of major depressive disorder by paroxetine combined with chaihu xiaoyao mixture]
    Zheng Hui Yi
    Shanghai Mental Health Center, Medical School of Shanghai Jiaotong University, Shanghai 201108
    Zhongguo Zhong Xi Yi Jie He Za Zhi 30:1257-60. 2010
    ..To evaluate the efficacy and safety of Chaihu Xiaoyao Mixture (CXM) for the treatment of major depressive disorder (MDD)...
  76. doi Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design
    Marc L M van der Loos
    Department of Psychiatry, Isala Klinieken Location Sophia, Zwolle, The Netherlands
    Bipolar Disord 13:111-7. 2011
    ..we described the efficacy of lamotrigine versus placebo as add-on to lithium (followed by the addition of paroxetine in nonresponders) in the short-term treatment of bipolar depression...
  77. ncbi Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study
    A Bertani
    Anxiety Disorder Clinical and Research Unit, Department of Neuropsychiatric Sciences, Vita Salute University, Istituto Scientifico Ospedale San Raffaele, Milan, Italy
    Pharmacopsychiatry 37:206-10. 2004
    ..However preliminary studies suggested that reboxetine might be effective in the treatment of PD. We compared the effectiveness and tolerability of reboxetine and paroxetine in the treatment of PD.
  78. ncbi The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression
    Andre Tadic
    Department of Psychiatry, University of Mainz, Mainz, Germany
    Am J Med Genet B Neuropsychiatr Genet 144:325-31. 2007
    ..association of the MAOA T941G gene variant with differential antidepressant response to mirtazapine and/or paroxetine in 102 patients with major depression (DSM-IV criteria) participating in a randomized double-blind controlled ..
  79. ncbi Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?
    Daniel A Geller
    Obsessive Compulsive Disorder Program, Pediatric Psychopharmacology Research Program, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Child Adolesc Psychopharmacol 13:S19-29. 2003
    To examine the influence of psychiatric comorbidity on response and relapse rates in children and adolescents treated with paroxetine for obsessive-compulsive disorder (OCD).
  80. ncbi Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram
    S J Wilson
    Psychopharmacology Unit, University of Bristol, University Walk, Bristol BS8 1TD, UK
    Eur Neuropsychopharmacol 14:367-72. 2004
    ..Although in the UK, paroxetine (PAR) and citalopram (CIT) have recommended doses of 20 mg/day for the treatment of depression, the recommended ..
  81. ncbi Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions
    Dan J Stein
    University of Cape Town, South Africa and University of Florida, Gainesville, USA
    Eur Neuropsychopharmacol 16:33-8. 2006
    ..This paper examines data from a fixed-dose trial of escitalopram versus paroxetine, in order to determine the differential effects of these agents on symptom dimensions in social anxiety disorder ..
  82. ncbi Toxic hepatitis associated with paroxetine
    O Colakoglu
    Gastroenterology Clinics, Ataturk Training and Research Hospital, Izmir, Turkey
    Int J Clin Pract 59:861-2. 2005
    Hepatotoxicity is a rare complication of paroxetine, a selective serotonin reuptake inhibitor...
  83. ncbi Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism
    Masaki Kato
    Department of Neuropsychiatry, Kansai Medical University, Moriguchi, Osaka, Japan
    Int Clin Psychopharmacol 20:151-6. 2005
    ..Clinical responses to paroxetine and fluvoxamine were evaluated by total and cluster depressive symptoms for 81 Japanese patients who were ..
  84. ncbi Triiodothyronine addition to paroxetine in the treatment of major depressive disorder
    Bente C Appelhof
    Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, 1100 DE Amsterdam, The Netherlands
    J Clin Endocrinol Metab 89:6271-6. 2004
    ..This is the first study to investigate the efficacy of T3 addition to paroxetine in major depression...
  85. ncbi Recurrent paroxetine-induced hyponatremia
    Asif R Malik
    Can J Psychiatry 49:785. 2004
  86. ncbi Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine
    Mikael Landen
    Section of Psychiatry St Göran, Department of Clinical Neuroscience, Karolinska Institutet, SE 112 81, Stockholm, Sweden
    J Clin Psychiatry 66:100-6. 2005
    ....
  87. ncbi Structural differences between paroxetine and femoxetine responsible for differential inhibition of Staphylococcus aureus efflux pumps
    Peng Wei
    Division of Medicinal and Natural Products Chemistry, The University of Iowa, Iowa City, IA 52242, USA
    Bioorg Med Chem Lett 14:3093-7. 2004
    In this study the chemical modification of paroxetine was employed to determine which structural differences between the paroxetine-like and femoxetine-like selective serotonin reuptake inhibitors is responsible for the differential ..
  88. ncbi An open trial of paroxetine for the "offensive subtype" of taijin kyofusho and social anxiety disorder
    Toshihiko Nagata
    Department of Neuropsychiatry, Osaka City University Medical School, Osaka, Japan
    Depress Anxiety 23:168-74. 2006
    ..This study investigated the efficacy of the SSRI paroxetine in patients with the TKS offensive subtype, both on anxiety and fears, as well as insight...
  89. ncbi State markers of depression in sleep EEG: dependency on drug and gender in patients treated with tianeptine or paroxetine
    H Murck
    Max Planck Institute of Psychiatry, Munich, Germany
    Neuropsychopharmacology 28:348-58. 2003
    Tianeptine enhances while paroxetine inhibits serotonin reuptake into neurons; however, both show an antidepressive action...
  90. ncbi Proteomic analysis of embryonic stem cell-derived neural cells exposed to the antidepressant paroxetine
    Patrick C McHugh
    Department of Pathology, University of Otago, Christchurch, New Zealand
    J Neurosci Res 86:306-16. 2008
    ..and glial cells by controlled differentiation of mouse embryonic stem cells, followed by exposure to 1 microM paroxetine for 14 days...
  91. ncbi A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers
    Eduard Vieta
    Bipolar Disorders Program, Barcelona Stanley Foundation Research Center, IDIBAPS, Hospital Clinic, University of Barcelona, Spain
    J Clin Psychiatry 63:508-12. 2002
    ..This study was aimed to assess and compare the efficacy and safety of 2 different antidepressant drugs, paroxetine and venlafaxine, in this indication.
  92. ncbi Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study
    M E Henry
    McLean Hospital, Belmont, MA 02478, USA
    Am J Psychiatry 157:1506-8. 2000
    ..This study tested whether a relationship exists between concentration and response following discontinuation of selective serotonin reuptake inhibitors...
  93. ncbi MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression
    Alma Mihaljevic Peles
    Department of Psychiatry, Zagreb University Hospital and University School of Medicine, Kispaticeva 12, 10 000 Zagreb, Croatia
    Prog Neuropsychopharmacol Biol Psychiatry 32:1439-44. 2008
    ..the potential influence of MDR1 polymorphisms, exon 26 C3435T and exon 21 G2677T/A, on treatment response to paroxetine (20 mg/day) in patients with major depression...
  94. ncbi ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder
    Masaki Kato
    Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan
    Prog Neuropsychopharmacol Biol Psychiatry 32:398-404. 2008
    ..3 functional ABCB1 polymorphisms (C3435T: rs1045642, G2677T/A: rs2032582 and C1236T: rs1128503) with response to paroxetine in a Japanese major depression sample followed for 6 weeks...
  95. ncbi Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity
    U W Preuss
    Department of Psychiatry, Ludwig Maximilians Universitat Munchen, Nussbaumstr 7, 80336, Munchen, Germany
    Psychiatry Res 96:51-61. 2000
    The aim of this study was to investigate [3H]paroxetine binding and impulsivity in alcohol-dependent and age-matched control subjects in relation to a 5'-promoter region serotonin transporter (5-HTT) polymorphism (5-HTTLPR)...
  96. ncbi The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain
    C Dickens
    Department of Psychiatry, Manchester University, UK
    Psychosomatics 41:490-9. 2000
    ..Using a placebo-controlled trial, the authors examined the analgesic and antidepressant efficacy of paroxetine (20 mg) in chronic low back pain sufferers...
  97. ncbi Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study
    R Zanardi
    Istituto Scientifico Ospedale San Raffaele, Department of Neuropsychiatric Sciences, School of Medicine, University of Milan, Italy
    J Clin Psychopharmacol 21:53-8. 2001
    ..binding of [18F]fluoro-ethyl-spiperone after a 4-week treatment with the selective serotonin reuptake inhibitor paroxetine. [18F]fluoro-ethyl-spiperone labels 5-HT2A receptors in the cortex and dopamine D2 receptors in the basal ..
  98. pmc Neonatal paroxetine withdrawal syndrome
    J A Stiskal
    Division of Neonatology, Morristown Memorial Hospital, Morristown, New Jersey, USA
    Arch Dis Child Fetal Neonatal Ed 84:F134-5. 2001
    Four term neonates presented with symptoms such as jitteriness and necrotising enterocolitis after paroxetine exposure in utero.
  99. ncbi Paroxetine
    Siu Wa Tang
    University of California, Psychiatry North Campus Zot 1681, Irvine, California 92697 1681, USA
    Expert Opin Pharmacother 9:787-94. 2008
    b>Paroxetine is a widely used antidepressant that has received attention regarding suicide risk in younger patients.
  100. ncbi Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial
    M H Pollack
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    J Clin Psychiatry 62:350-7. 2001
    The objective of this randomized, double-blind, placebo-controlled study was to investigate the efficacy and safety of paroxetine in outpatients with generalized anxiety disorder (GAD).
  101. ncbi Tryptophan hydroxylase gene associated with paroxetine antidepressant activity
    A Serretti
    Department of Psychiatry, Vita Salute University, San Raffaele Institute, Via Stamira D Ancona 20 20127 Milan, Italy
    Eur Neuropsychopharmacol 11:375-80. 2001
    ..possible association of the A218C tryptophan hydroxylase (TPH) gene variant with the antidepressant activity of paroxetine was investigated in a sample of 121 inpatients affected by a major depressive episode and treated with ..

Research Grants104 found, 100 shown here

  1. 5-HT1A RECEPTOR/G PROTEIN COUPLING AND ADAPTATION
    Emanuel Meller; Fiscal Year: 2003
    ..in forebrain regions will be assessed to test the hypothesis that repeated treatment (21 days) with ipsapirone, paroxetine or clorgyline (but not imipramine) will desensitize somatodendritic 5-HT1A autoreceptors and reduce agonist-..
  2. Serotonin Receptor Modulation of Neurotrophic Factors in the Retina
    Mark E Pennesi; Fiscal Year: 2013
    ..SSRIs, such as fluoxetine or paroxetine, have been widely and safely used to treat a number of psychiatric diseases such as depression and anxiety...
  3. GENETIC ANALYSIS OF NEMATODE EGG LAYING
    HOWARD R HORVITZ; Fiscal Year: 2010
    ....
  4. The Effect of Genetic Diversity on Mechanism-Based Inactivation of CYP2D6
    Laura L Furge; Fiscal Year: 2013
    ..normal and inactivator substrates including two protein adductors (SCH66712 and EMTPP) and two heme modifiers (paroxetine and MDMA). Aim 2: To determine the interaction of the most common polymorphisms of CYP2D6 with inactivators...
  5. Pharmacogenetics of the Antidepressant Response in Geriatric Major Depression
    Greer M Murphy; Fiscal Year: 2010
    ..intact patients 65 years of age and older with major depression who were treated with either mirtazapine or paroxetine for 24 weeks...
  6. Pharmacogenetics of the Antidepressant Response in Geriatric Major Depression
    Greer M Murphy; Fiscal Year: 2010
    ..intact patients 65 years of age and older with major depression who were treated with either mirtazapine or paroxetine for 24 weeks...
  7. Modeling Neural Injury Effects of Methamphetamine Metabolism by CYP2D6 in HIV
    Mariana Cherner; Fiscal Year: 2013
    ..3) examine how these results are affected by exposure of the cultures to clinically relevant CYP2D6 inhibitors (paroxetine and ritonavir)...
  8. PSYCHOSTIMULANT RECOGNITION BY SEROTONIN TRANSPORTERS
    Eric L Barker; Fiscal Year: 2010
    ..most antidepressant drugs as well as many drugs of abuse. Antidepressants such as paroxetine, fluoxetine, and imipramine bind to the transporter and inhibit serotonin uptake, thereby prolonging the ..
  9. Efficacy of an Acute Exercise Intervention for Side Effects of SSRIs
    Tierney K Ahrold; Fiscal Year: 2010
    ..different neurotransmitter selectivity profiles, we will recruit equal numbers of women taking sertraline, paroxetine, or citalopram (highly selective for serotonin relative to norephinephrine) and venlafaxine or duloxetine (..
  10. MSI-FLASH: Relative Efficacy of Hormonal and Non-Hormonal Interventions for VMS
    Hadine Joffe; Fiscal Year: 2010
    ..test the relative efficacy of low-dose estrogen therapy and the selective serotonin-reuptake inhibitor (SSRI) paroxetine for the treatment of hot flashes...
  11. Serotonin in Stress Indued Bladder Hypersensitivity
    Meredith T Robbins; Fiscal Year: 2013
    ..will expand upon preliminary studies and will assess the effect of systemic administration of an SSRI, paroxetine, and an SNRI, milnacipram, on stress-induced bladder hypersensitivity, measured by urinary bladder distension-..
  12. Trial of paroxetine as adjuvant treatment for atopic dermatitis symptoms
    Calvin McCall; Fiscal Year: 2002
    ..The goals of this investigation are to determine if 12 weeks of paroxetine will 1a) diminish the pruritus associated with moderate to severe AD, 1b) diminish AD associated skin severity, ..
  13. DRUG TREATMENT OF COEXISTING PANIC AND MAJOR DEPRESSION
    ROBERT LYDIARD; Fiscal Year: 1999
    ..comorbid disorder, and to assess the clinical comparative efficacy of a selective serotonin uptake inhibitor, paroxetine, 224 patients identified by use of the Structured Clinical Interview for DSMIII-R (SCID) as having both panic ..
  14. 5-HT1A RECEPTOR/G PROTEIN COUPLING AND ADAPTATION
    Emanuel Meller; Fiscal Year: 2000
    ..in forebrain regions will be assessed to test the hypothesis that repeated treatment (21 days) with ipsapirone, paroxetine or clorgyline (but not imipramine) will desensitize somatodendritic 5-HT1A autoreceptors and reduce agonist-..
  15. 5-HT1A RECEPTOR/G PROTEIN COUPLING AND ADAPTATION
    Emanuel Meller; Fiscal Year: 2002
    ..in forebrain regions will be assessed to test the hypothesis that repeated treatment (21 days) with ipsapirone, paroxetine or clorgyline (but not imipramine) will desensitize somatodendritic 5-HT1A autoreceptors and reduce agonist-..
  16. 5-HT1A RECEPTOR/G PROTEIN COUPLING AND ADAPTATION
    Emanuel Meller; Fiscal Year: 2001
    ..in forebrain regions will be assessed to test the hypothesis that repeated treatment (21 days) with ipsapirone, paroxetine or clorgyline (but not imipramine) will desensitize somatodendritic 5-HT1A autoreceptors and reduce agonist-..
  17. COCAINE & SEROTONIN NEUROCHEMISTRY
    DONALD KUHN; Fiscal Year: 1991
    ..In one aim, binding of 3H-paroxetine will be used to determine if cocaine alters either the affinity of the 5HT transporter for 5HT or the number of ..
  18. COCAINE & SEROTONIN NEUROCHEMISTRY
    DONALD KUHN; Fiscal Year: 1993
    ..In one aim, binding of 3H-paroxetine will be used to determine if cocaine alters either the affinity of the 5HT transporter for 5HT or the number of ..
  19. Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction
    Cindy Meston; Fiscal Year: 2002
    ..female sexual arousal disorder, and/or inhibited female orgasm secondary to either to fluoxetine, sertraline, or paroxetine use...
  20. Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction
    Cindy Meston; Fiscal Year: 2001
    ..female sexual arousal disorder, and/or inhibited female orgasm secondary to either to fluoxetine, sertraline, or paroxetine use...
  21. Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction
    Cindy Meston; Fiscal Year: 2003
    ..female sexual arousal disorder, and/or inhibited female orgasm secondary to either to fluoxetine, sertraline, or paroxetine use...
  22. SEROTONIN UPTAKE INHIBITOR LIGANDS FOR PET STUDIES
    Chester Mathis; Fiscal Year: 1990
    ..Various cold (nonradioactive) chemical analogs of paroxetine, a serotonin presynaptic uptake site inhibitor, will be synthesized...
  23. R21 Project: St. John's Wort vs. Placebo in OCD
    Kenneth Kobak; Fiscal Year: 2003
    ..g., drop-out rates in the multi-center trials of fluoxetine, fluvoxamine, sertraline, and paroxetine were 23%, 24%, 27%, and 20% respectively. There has been considerable worldwide interest in St...
  24. R21 Project: St. John's Wort vs. Placebo in OCD
    Kenneth Kobak; Fiscal Year: 2002
    ..g., drop-out rates in the multi-center trials of fluoxetine, fluvoxamine, sertraline, and paroxetine were 23%, 24%, 27%, and 20% respectively. There has been considerable worldwide interest in St...
  25. Maintenance Therapies in Late-Life Depression-III
    Charles Reynolds; Fiscal Year: 2004
    ..of memory and of executive functions despite continued recovery from depression on SSRI pharmacotherapy with paroxetine. Therefore, in MTLD-III, we will test a pharmacologic strategy involving the cholinesterase inhibitor (ChEI) ..
  26. SEROTONIN RECEPTORS IN SUICIDES WITH PSYCHIATRIC AUTOPSY
    Craig Stockmeier; Fiscal Year: 1990
    ..4. To determine with in vitro quantitative autoradiography whether the high-affinity binding of {3H}paroxetine to the 5-HT transporter complex in sections of frontal cortex of violent and nonviolent suicide completers is ..
  27. Efficacy of an Acute Exercise Intervention for Side Effects of SSRIs
    Tierney Ahrold; Fiscal Year: 2009
    ..different neurotransmitter selectivity profiles, we will recruit equal numbers of women taking sertraline, paroxetine, or citalopram (highly selective for serotonin relative to norephinephrine) and venlafaxine or duloxetine (..
  28. GERIATRIC DEPRESSION--NEUROBIOLOGY OF TREATMENT
    Charles Reynolds; Fiscal Year: 2001
    ..We hypothesize that therapeutic sleep deprivation (TSD) will accelerate response to paroxetine (PX), as compared with TSD (+ placebo) or with PX alone...
  29. GERIATRIC DEPRESSION--NEUROBIOLOGY OF TREATMENT
    Charles Reynolds; Fiscal Year: 2002
    ..We hypothesize that therapeutic sleep deprivation (TSD) will accelerate response to paroxetine (PX), as compared with TSD (+ placebo) or with PX alone...
  30. GERIATRIC DEPRESSION--NEUROBIOLOGY OF TREATMENT
    Charles Reynolds; Fiscal Year: 2000
    ..We hypothesize that therapeutic sleep deprivation (TSD) will accelerate response to paroxetine (PX), as compared with TSD (+ placebo) or with PX alone...
  31. GERIATRIC DEPRESSION--NEUROBIOLOGY OF TREATMENT
    Charles Reynolds; Fiscal Year: 2003
    ..We hypothesize that therapeutic sleep deprivation (TSD) will accelerate response to paroxetine (PX), as compared with TSD (+ placebo) or with PX alone...
  32. GERIATRIC DEPRESSION--NEUROBIOLOGY OF TREATMENT
    Charles Reynolds; Fiscal Year: 1999
    ..We hypothesize that therapeutic sleep deprivation (TSD) will accelerate response to paroxetine (PX), as compared with TSD (+ placebo) or with PX alone...
  33. Paradoxical Antidepressant Action in Locus Coeruleus during Development
    JAY WEISS; Fiscal Year: 2009
    ..to juveniles (children and adolescents), (2) use of selective serotonin reuptake inhibitors (SSRIs), especially paroxetine, and (3) effects during the early course of AD treatment...
  34. Paradoxical Antidepressant Action in Locus Coeruleus during Development
    JAY WEISS; Fiscal Year: 2007
    ..to juveniles (children and adolescents), (2) use of selective serotonin reuptake inhibitors (SSRIs), especially paroxetine, and (3) effects during the early course of AD treatment...
  35. GENETIC ANALYSIS OF NEMATODE EGG LAYING
    H Horvitz; Fiscal Year: 2009
    ....
  36. COGNITIVE THERAPY AND PHARMACOTHERAPY FOR DEPRESSION
    STEVEN HOLLON; Fiscal Year: 2000
    ..The PT condition entails the use of paroxetine, augmented by lithium carbonate after eight weeks for those patients who do not respond to desipramine by that ..
  37. COGNITIVE THERAPY AND PHARMACOTHERAPY FOR DEPRESSION
    ROBERT DERUBEIS; Fiscal Year: 1999
    ..The PT condition entails the use of paroxetine, augmented by lithium carbonate after eight weeks for those patients who do not respond to desipramine by that ..
  38. COGNITIVE THERAPY AND PHARMACOTHERAPY FOR DEPRESSION
    ROBERT DERUBEIS; Fiscal Year: 2000
    ..The PT condition entails the use of paroxetine, augmented by lithium carbonate after eight weeks for those patients who do not respond to desipramine by that ..
  39. COGNITIVE THERAPY AND PHARMACOTHERAPY FOR DEPRESSION
    STEVEN HOLLON; Fiscal Year: 1999
    ..The PT condition entails the use of paroxetine, augmented by lithium carbonate after eight weeks for those patients who do not respond to desipramine by that ..
  40. SEROTONIN RECEPTOR LIGANDS FOR SPECT IMAGING
    HANK KUNG; Fiscal Year: 2003
    ..prescribed antidepressants, selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, sertraline and paroxetine, modulate 5-HT neurotransmission by blocking the serotonin transporters (SERT)...
  41. SEROTONIN RECEPTOR LIGANDS FOR SPECT IMAGING
    HANK KUNG; Fiscal Year: 2002
    ..prescribed antidepressants, selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, sertraline and paroxetine, modulate 5-HT neurotransmission by blocking the serotonin transporters (SERT)...
  42. TREATMENT OF PANIC DISORDER--LONG TERM STRATEGIES
    David Barlow; Fiscal Year: 2002
    ..Non-responders will be randomized to a study comparing paroxetine with continued CBT...
  43. TREATMENT OF PANIC DISORDER--LONG TERM STRATEGIES
    David Barlow; Fiscal Year: 2003
    ..Non-responders will be randomized to a study comparing paroxetine with continued CBT...
  44. SEROTONIN RECEPTOR LIGANDS FOR SPECT IMAGING
    HANK KUNG; Fiscal Year: 2004
    ..prescribed antidepressants, selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, sertraline and paroxetine, modulate 5-HT neurotransmission by blocking the serotonin transporters (SERT)...
  45. TREATMENT OF PANIC DISORDER LONG TERM STRATEGIES
    M Shear; Fiscal Year: 2001
    ..Non-responders will be randomized to a study comparing paroxetine with continued CBT...
  46. TREATMENT OF PANIC DISORDER--LONG TERM STRATEGIES
    David Barlow; Fiscal Year: 2000
    ..Non-responders will be randomized to a study comparing paroxetine with continued CBT...
  47. TREATMENT OF PANIC DISORDER--LONG TERM STRATEGIES
    David Barlow; Fiscal Year: 1999
    ..Non-responders will be randomized to a study comparing paroxetine with continued CBT...
  48. MECHANISM OF DEPRESSIVE BEHAVIOR IN WISTAR-KYOTO RATS
    Shanaz Tejani Butt; Fiscal Year: 2001
    ..Treatment with desipramine (a NE uptake blocker), but not paroxetine (a 5-HT uptake blocker), decreased immobility time in the Porsolt forced swim test, and reduced ulcer incidence, ..
  49. TREATMENT OF PANIC DISORDER LONG TERM STRATEGIES
    M Shear; Fiscal Year: 2002
    ..Non-responders will be randomized to a study comparing paroxetine with continued CBT...
  50. SEROTONIN RECEPTOR LIGANDS FOR SPECT IMAGING
    HANK KUNG; Fiscal Year: 2000
    ..prescribed antidepressants, selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, sertraline and paroxetine, modulate 5-HT neurotransmission by blocking the serotonin transporters (SERT)...
  51. TREATMENT OF PANIC DISORDER--LONG TERM STRATEGIES
    David Barlow; Fiscal Year: 2001
    ..Non-responders will be randomized to a study comparing paroxetine with continued CBT...
  52. SEROTONIN RECEPTOR LIGANDS FOR SPECT IMAGING
    HANK KUNG; Fiscal Year: 2001
    ..prescribed antidepressants, selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, sertraline and paroxetine, modulate 5-HT neurotransmission by blocking the serotonin transporters (SERT)...
  53. TREATMENT OF PANIC DISORDER LONG TERM STRATEGIES
    M Shear; Fiscal Year: 1999
    ..Non-responders will be randomized to a study comparing paroxetine with continued CBT...
  54. TREATMENT OF PANIC DISORDER LONG TERM STRATEGIES
    M Shear; Fiscal Year: 2003
    ..Non-responders will be randomized to a study comparing paroxetine with continued CBT...
  55. PSYCHOSTIMULANT RECOGNITION BY SEROTONIN TRANSPORTERS
    ERIC BARKER; Fiscal Year: 2006
    ..Antidepressants such as paroxetine, fluoxetine, and imipramine bind to the transporter and inhibit serotonin uptake, thereby prolonging the ..
  56. PSYCHOSTIMULANT RECOGNITION BY SEROTONIN TRANSPORTERS
    ERIC BARKER; Fiscal Year: 2009
    ..most antidepressant drugs as well as many drugs of abuse. Antidepressants such as paroxetine, fluoxetine, and imipramine bind to the transporter and inhibit serotonin uptake, thereby prolonging the ..
  57. METHOD FOR MAKING AN IMPROVED ST JOHN'S WORT PRODUCT
    TREVOR CASTOR; Fiscal Year: 2000
    ..8 billion antidepressant marketplace. ..
  58. METHOD FOR MAKING AN IMPROVED ST JOHN'S WORT PRODUCT
    TREVOR CASTOR; Fiscal Year: 2001
    ..8 billion antidepressant marketplace. ..
  59. METHOD FOR MAKING AN IMPROVED ST JOHN'S WORT PRODUCT
    TREVOR CASTOR; Fiscal Year: 1999
    ..8 billion antidepressant marketplace. ..
  60. St. John's Wort vs Placebo in Social Phobia
    Kenneth Kobak; Fiscal Year: 2001
    ..However, side effects with these compounds suggests the need for better tolerated compounds, e.g., in the paroxetine multi-center trial (the only drug with an FDA approved indication), 27 percent reported somnolence, 26 percent ..
  61. St. John's Wort vs Placebo in Social Phobia
    Kenneth Kobak; Fiscal Year: 2002
    ..However, side effects with these compounds suggests the need for better tolerated compounds, e.g., in the paroxetine multi-center trial (the only drug with an FDA approved indication), 27 percent reported somnolence, 26 percent ..
  62. MLSN Screen of the PD Alpha Synuclein 5'UTR
    Jack Rogers; Fiscal Year: 2007
    ..of neurodegenerative disease transcripts, our APP 5'UTR screens generated drug selectivity since paroxetine was an APP 5'UTR directed FDA inhibitor that did not change APLP-1 and APLP-2 expression in SH-SY5Y cells (..
  63. SPOUSAL ABUSE--SEROTONERGIC STUDIES AND TREATMENT
    EMIL COCCARO; Fiscal Year: 1999
    ..will include d- Fenfluramine Challenge (CSF 5-HIAA in a subgroup) and Platelet measures of 5-HT Uptake (3H-Paroxetine Binding) and 5-HT-2 receptors (125I-LSD Binding) to simultaneously assess multiple aspects of 3-HT system ..
  64. SPOUSAL ABUSE--SEROTONERGIC STUDIES AND TREATMENT
    EMIL COCCARO; Fiscal Year: 1999
    ..will include d- Fenfluramine Challenge (CSF 5-HIAA in a subgroup) and Platelet measures of 5-HT Uptake (3H-Paroxetine Binding) and 5-HT-2 receptors (125I-LSD Binding) to simultaneously assess multiple aspects of 3-HT system ..
  65. EFFECT OF REPEATED MDMA ADMINISTRATION ON 5-HT FUNCTION
    CHARLES ASHBY; Fiscal Year: 1993
    ..or nerve terminal destruction produced by MDMA will be determined by receptor autoradiography using 3H-paroxetine binding, which labels 5-HT uptake sites. Finally, we will assess various indices of serotonergic function 0...
  66. NEUROANATOMY AND PHARMACOTHERAPY OF OCD AND MAJOR DEPRES
    Sanjaya Saxena; Fiscal Year: 1999
    ..brain system mediation of OCD symptoms and MDD symptoms occurring simultaneously, in patients treated with paroxetine, a medication shown to be effective for both disorders...
  67. NEUROANATOMY AND PHARMACOTHERAPY OF OCD AND MAJOR DEPRES
    Sanjaya Saxena; Fiscal Year: 2001
    ..brain system mediation of OCD symptoms and MDD symptoms occurring simultaneously, in patients treated with paroxetine, a medication shown to be effective for both disorders...
  68. NEUROANATOMY AND PHARMACOTHERAPY OF OCD AND MAJOR DEPRES
    Sanjaya Saxena; Fiscal Year: 2002
    ..brain system mediation of OCD symptoms and MDD symptoms occurring simultaneously, in patients treated with paroxetine, a medication shown to be effective for both disorders...
  69. The Synthesis of Bioactive Polycyclic Natural Products
    Brian M Stoltz; Fiscal Year: 2010
    ..Specifically, we outline approaches to dichroanone, liphagal, cyanthiwigin G, platensimycin, paroxetine, and ineleganolide...
  70. NEUROANATOMY AND PHARMACOTHERAPY OF OCD AND MAJOR DEPRES
    Sanjaya Saxena; Fiscal Year: 2000
    ..brain system mediation of OCD symptoms and MDD symptoms occurring simultaneously, in patients treated with paroxetine, a medication shown to be effective for both disorders...
  71. Maintenance Therapies in Late-Life Depression-III
    Bruce Pollock; Fiscal Year: 2007
    ..of memory and of executive functions despite continued recovery from depression on SSRI pharmacotherapy with paroxetine. Therefore, in MTLD-III, we will test a pharmacologic strategy involving the cholinesterase inhibitor (ChEI) ..
  72. Maintenance Therapies in Late-Life Depression-III
    Bruce Pollock; Fiscal Year: 2005
    ..of memory and of executive functions despite continued recovery from depression on SSRI pharmacotherapy with paroxetine. Therefore, in MTLD-III, we will test a pharmacologic strategy involving the cholinesterase inhibitor (ChEI) ..
  73. Maintenance Therapies in Late-Life Depression-III
    Bruce Pollock; Fiscal Year: 2006
    ..of memory and of executive functions despite continued recovery from depression on SSRI pharmacotherapy with paroxetine. Therefore, in MTLD-III, we will test a pharmacologic strategy involving the cholinesterase inhibitor (ChEI) ..
  74. RATIONAL PHARMACOTHERAPY OF PRIMARY INSOMNIA
    Daniel Buysse; Fiscal Year: 2000
    ..activities will focus on design and implementation of a treatment trial comparing a Bz (zolpidem) and an AD (paroxetine) versus placebo for the acute and maintenance treatment of PI...
  75. RATIONAL PHARMACOTHERAPY OF PRIMARY INSOMNIA
    Daniel Buysse; Fiscal Year: 2002
    ..activities will focus on design and implementation of a treatment trial comparing a Bz (zolpidem) and an AD (paroxetine) versus placebo for the acute and maintenance treatment of PI...
  76. RATIONAL PHARMACOTHERAPY OF PRIMARY INSOMNIA
    Daniel Buysse; Fiscal Year: 2003
    ..activities will focus on design and implementation of a treatment trial comparing a Bz (zolpidem) and an AD (paroxetine) versus placebo for the acute and maintenance treatment of PI...
  77. RATIONAL PHARMACOTHERAPY OF PRIMARY INSOMNIA
    Daniel Buysse; Fiscal Year: 2001
    ..activities will focus on design and implementation of a treatment trial comparing a Bz (zolpidem) and an AD (paroxetine) versus placebo for the acute and maintenance treatment of PI...
  78. RATIONAL PHARMACOTHERAPY OF PRIMARY INSOMNIA
    Daniel Buysse; Fiscal Year: 2004
    ..activities will focus on design and implementation of a treatment trial comparing a Bz (zolpidem) and an AD (paroxetine) versus placebo for the acute and maintenance treatment of PI...
  79. ANTIDEPRESSANTS IN BREASTFEEDING WOMEN
    Victoria Hendrick; Fiscal Year: 1999
    ..mothers on selective-serotonin-reuptake-inhibitor (SSRI) antidepressant medications (sertraline, fluoxetine, and paroxetine)...
  80. ANTIDEPRESSANTS IN BREASTFEEDING WOMEN
    Victoria Hendrick; Fiscal Year: 2001
    ..mothers on selective-serotonin-reuptake-inhibitor (SSRI) antidepressant medications (sertraline, fluoxetine, and paroxetine)...
  81. ANTIDEPRESSANTS IN BREASTFEEDING WOMEN
    Victoria Hendrick; Fiscal Year: 2000
    ..mothers on selective-serotonin-reuptake-inhibitor (SSRI) antidepressant medications (sertraline, fluoxetine, and paroxetine)...
  82. DRUG ABUSE, SLEEP AND COGNITION
    J Hobson; Fiscal Year: 2000
    ..drug classes, the psychostimulants (here cocaine) and the selective serotonin reuptake inhibitors or SSRIs (here paroxetine), both of which are known to potentiate the monoaminergic neuronal systems of the brain...
  83. AFFECT, DEPRESSION AND BRAIN ASYMMETRY
    Richard Davidson; Fiscal Year: 1999
    ..First during an acute episode when all patients are off medication. Second, patients will then be treated with paroxetine and will be retested after meeting criteria for recovery...
  84. DRUG ABUSE, SLEEP AND COGNITION
    J Hobson; Fiscal Year: 1999
    ..drug classes, the psychostimulants (here cocaine) and the selective serotonin reuptake inhibitors or SSRIs (here paroxetine), both of which are known to potentiate the monoaminergic neuronal systems of the brain...
  85. AFFECT, DEPRESSION AND BRAIN ASYMMETRY
    Richard Davidson; Fiscal Year: 2000
    ..First during an acute episode when all patients are off medication. Second, patients will then be treated with paroxetine and will be retested after meeting criteria for recovery...
  86. DRUG ABUSE, SLEEP AND COGNITION
    J Hobson; Fiscal Year: 2002
    ..drug classes, the psychostimulants (here cocaine) and the selective serotonin reuptake inhibitors or SSRIs (here paroxetine), both of which are known to potentiate the monoaminergic neuronal systems of the brain...
  87. NEUROBIOLOGICAL STUDIES OF ECT IN DEPRESSION
    JOSEPH MANN; Fiscal Year: 2001
    ..ECT and paroxetine had different effects on relative regional brain glucose uptake following placebo or fenfluramine...
  88. Prazosin for Noncombat Trauma PTSD
    Murray Raskind; Fiscal Year: 2005
    ..and sleep disturbance that persist despite a trial of the selective serotonin reuptake inhibitor (SSRI) paroxetine. Although several SSRIs are FDA-approved for PTSD, SSRIs (and other drugs) often are not helpful for these very ..
  89. Prazosin for Noncombat Trauma PTSD
    Murray Raskind; Fiscal Year: 2006
    ..and sleep disturbance that persist despite a trial of the selective serotonin reuptake inhibitor (SSRI) paroxetine. Although several SSRIs are FDA-approved for PTSD, SSRIs (and other drugs) often are not helpful for these very ..
  90. NEUROBIOLOGICAL STUDIES OF ECT IN DEPRESSION
    JOSEPH MANN; Fiscal Year: 2000
    ..ECT and paroxetine had different effects on relative regional brain glucose uptake following placebo or fenfluramine...
  91. Prazosin for Noncombat Trauma PTSD
    Murray Raskind; Fiscal Year: 2007
    ..and sleep disturbance that persist despite a trial of the selective serotonin reuptake inhibitor (SSRI) paroxetine. Although several SSRIs are FDA-approved for PTSD, SSRIs (and other drugs) often are not helpful for these very ..
  92. NEUROBIOLOGICAL STUDIES OF ECT IN DEPRESSION
    JOSEPH MANN; Fiscal Year: 1999
    ..ECT and paroxetine had different effects on relative regional brain glucose uptake following placebo or fenfluramine...